Fastende plasmaglucoseniveauer er signifikant lavere hos patienter, der behandles med EXUBERA end hos dem, der kun behandles med subkutant indgivet hurtigtvirkende humant insulin. læ
Fasting plasma glucose levels were significantly lower in patients treated with regimens including EXUBERA compared with those treated with subcutaneously administered fast-acting human insulin only regimens.